Skip to main content

TRULICITY (Eli Lilly Australia Pty Ltd)

Product name
TRULICITY
Date registered
Evaluation commenced
Decision date
Approval time
158 working days (175 COR-B)
Active ingredients
dulaglutide (rch)
Registration type
EOI
Indication

TRULICITY (solution for injection) is now also indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:

  • In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 5.1 for data with respect to different combinations).

Help us improve the Therapeutic Goods Administration site